ChromogenixCoatest®APC™Resistance–VisanAPTT-basedassaykitforthescreeningoffactor-V-relatedAPCresistance.ThehighsensitivityandspecificityofthetestforthefactorV:Q506mutationisobtainedbypredilutingthesampleplasmawithanexcessofV-DEFPlasmabioreagent.ThetestdesignmakesitpossIBLetodiscriminatebetweenheterozygousandhomozygousfactorVgenotypes.Italsoallowsforanalysisofplasmafrompatientsonheparinororalanticoagulanttherapy.Highdiscriminationbetweengenotypeswith100%sensitivityforFV:Q506.ReducesneedforPCRdetermination.Applicabletoanticoagulanttreatedpatients.
Atime-andmoney-savingalternativetoindividualgenetictesting,Coatest©APC™Resistancetestingisanidealsolutionforphysiciansandlabs.Eachkitwasdesignedtobeeasytouseforin-housescreening,offeringfastresultsandlowcostsforbothlarge-andsmall-volumelabs.ThemostcommonFVLeidenscreeningtestperformed,itoffersunmatchedsensitivityfortheFV:Q506mutation–closeto100%specificity–andisapplicabletopatientsonheparinorwarfarin.
OnevolumeofplasmaispredilutedwithfourvolumesofV-DEFPlasma.ThedilutionisthenincubatedwiththeAPTTreagentforastandardperiodoftime.CoagulationistriggeredbytheadditionofCaCl2intheabsenceandpresenceofexogenousAPCandthetimeforclotformationisrecorded.
ActivatedProteinC(APC)isaregulatorofthecoagulationcascade,byspecificallyinactivatingfactorsVaandVIIIa,inthepresenceofphospholipidsandcalcium. Inmostofthecases(morethan90%),ActivatedProteinCResistance(APCR)phenotypeiscausedbyaFactorVgenemutation(FactorVLeiden).Themutation,locatedonFactorVexon10(1691G–>A),ofargininetoglutamineonposition506,rendersFactorVaresistanttothecleavagebyActivatedProteinC.ThisgeneticanomalycanbeevidencedwithaclottingmethodperformedinthepresenceortheabsenceofActivatedProteinC.
Reagent | Size | Stability | Temp |
APC/CaCl2 | 4×2ml | 5days 8hours | 2-8°C 15-25°C |
APTTreagent | 1×16ml | 1week 1month | 15-25°C 2-8°C |
CaCl2 | 1×8ml | 1month 1week | 2-8°C 15-25°C |
V-DEFPlasma | 4×4ml | 8hours 24hours 3months | 15-25°C 2-8°C -20°C |
APC/CaCl2 | 4×2ml | 3months | -20°C |
ControlPlasmaLevel1 | 1×1ml | 6hours 3months | 2-25°C -20°C |
ControlPlasmaLevel2 | 1×1ml | 6hours 3months | 2-25°C -20°C |
Determinationsperkit:80–160
IDEALFOR:
TheChromogenixCoatestAPCResistanceVmethodwasusedforanalysisofplasmafromvarioussamplecategoriesshowingdiscriminationbetweennormalandmutatedfactorVgenotypes.
OAC=OralAnticoagulantTherapy
ActivatedProteinC(APC)isaregulatorofthecoagulationcascade,byspecificallyinactivatingfactorsVaandVIIIa,inthepresenceofphospholipidsandcalcium.
Inmostofthecases(morethan90%),ActivatedProteinCResistance(APCR)phenotypeiscausedbyaFactorVgenemutation(FactorVLeiden).Themutation,locatedonFactorVexon10(1691G–>A),ofargininetoglutamineonposition506,rendersFactorVaresistanttothecleavagebyActivatedProteinC.ThisgeneticanomalycanbeevidencedwithaclottingmethodperformedinthepresenceortheabsenceofActivatedProteinC.
ActivatedProteinCResistanceistestedbyusingaclottingmethodperformedwithorwithoutActivatedProteinC.
Readmore…
SouthernBiotech/Goat Anti-Human Lambda-Alexa Fluor® 555/2070-32/1.0 mg
vectorlabs/Biotinylated Aleuria Aurantia Lectin (AAL)/B-1395/1 mg
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Mouse IgG)/PK-6102/1 kit
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Universal)/PK-6200/1 kit
vectorlabs/Unconjugated Musa Paradisiaca (Banana) Lectin (BanLec)/L-1410/5 mg
GiottoBiotech/Calmodulin N60D/5 mg/G02CLM60cn